IMAAGEN Trial Update: Effect of Abiraterone Acetate and Low Dose Prednisone on PSA in Patients with Non-Metastatic Castration-Resistant Prostate Cancer

Charles Ryan presents an update to the IMAAGEN Trial which includes the percentage of patients with event-free rates for PSA progression at 12, 18, and 24 months and radiographic evidence of disease progression with non-metastatic castration-resistant prostate cancer when taking abiraterone acetate and low dose predisone.


Charles J. Ryan, MD is Professor of Clinical Medicine and Urology and the Clinical Program Leader for Genitourinary Medical Oncology at the UCSF Helen Diller Family Comprehensive Cancer Center. He received his MD from the University of Wisconsin in Madison and completed his residency in internal medicine at the University of Wisconsin Hospital and Clinics, where he also served as Chief Resident. He completed a fellowship in medical oncology in the Department of Medicine at Memorial Sloan-Kettering Cancer Center and the Joan and Sanford I. Weill Medical College of Cornell University in New York